-
公开(公告)号:US08592420B2
公开(公告)日:2013-11-26
申请号:US13447798
申请日:2012-04-16
申请人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
发明人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
IPC分类号: A61K31/50 , A61K31/505 , A61K31/41
CPC分类号: A61K45/06 , A61K31/00 , A61K31/519 , A61K31/522 , A61K2300/00
摘要: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要翻译: 通过施用有效量的至少一种腺苷A2A受体拮抗剂来治疗焦虑症,例如恐慌症,广场恐怖症,强迫症,社交恐惧症,创伤后应激障碍,广泛性焦虑症,特异性恐惧症等。 任选地与除了腺苷A2A受体拮抗剂之外的抗焦虑药组合。
-
公开(公告)号:US07851478B2
公开(公告)日:2010-12-14
申请号:US11916783
申请日:2006-06-07
申请人: Takako Kadowaki , Minoru Kobayashi , Shizuo Shiozaki , Naoki Seno
发明人: Takako Kadowaki , Minoru Kobayashi , Shizuo Shiozaki , Naoki Seno
IPC分类号: A61K31/505 , C07D491/00
CPC分类号: C07D487/04 , A61K31/519 , C07D487/14
摘要: For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine A2A receptor antagonistic action, which is represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, R2 represents a hydrogen atom, or the like, R3 represents —WR4, or the like, and Q1 represents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.
摘要翻译: 例如,作为活性成分,含有下述式(I)表示的腺苷A2A受体拮抗作用的三唑并嘧啶衍生物作为活性成分的预防和/或治疗运动障碍的药剂(其中,R1表示取代或未取代的芳基 或取代或未取代的杂环基,R2表示氢原子等,R3表示-WR4等,Q1表示氢原子或3,4-二甲氧基苄基)或其药学上可接受的盐, 喜欢被提供。
-
公开(公告)号:US20060241102A1
公开(公告)日:2006-10-26
申请号:US10565239
申请日:2004-07-22
申请人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
发明人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
IPC分类号: A61K31/551 , A61K31/5415 , A61K31/496 , A61K31/522
CPC分类号: A61K31/522 , A61K31/137 , A61K31/138 , A61K31/16 , A61K31/335 , A61K31/343 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/435 , A61K31/4525 , A61K31/496 , A61K31/52 , A61K31/5375 , A61K31/55 , A61K31/553 , A61K45/06 , A61K2300/00
摘要: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
摘要翻译: 本发明提供了可用于治疗抑郁症等的药物组合物,其包含具有腺苷A 2A受体拮抗活性的化合物,例如(E)-8-(3,4 - 二甲氧基苯乙烯基)-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮或其药学上可接受的盐和抗抑郁药(例如,三环抗抑郁药,四环抗抑郁药 ,选择性5-羟色胺再摄取抑制剂,选择性去甲肾上腺素再摄取抑制剂,多巴胺再摄取抑制剂,5-羟色胺去甲肾上腺素再摄取抑制剂,单胺氧化酶抑制剂,5-HT 2拮抗剂等),以及 喜欢。
-
公开(公告)号:US08034820B2
公开(公告)日:2011-10-11
申请号:US10565239
申请日:2004-07-22
申请人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
发明人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
IPC分类号: A01N43/90 , A01N43/52 , A61K31/522 , A61K31/415 , C07D473/00 , C07D403/02 , C07D317/44 , C07C211/00 , C07C213/00 , C07C215/00 , C07C217/00
CPC分类号: A61K31/522 , A61K31/137 , A61K31/138 , A61K31/16 , A61K31/335 , A61K31/343 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/435 , A61K31/4525 , A61K31/496 , A61K31/52 , A61K31/5375 , A61K31/55 , A61K31/553 , A61K45/06 , A61K2300/00
摘要: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
摘要翻译: 本发明提供了可用于治疗抑郁症等的药物组合物,其包含具有腺苷A2A受体拮抗活性的化合物,例如(E)-8-(3,4-二甲氧基苯乙烯基) 二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮或其药学上可接受的盐和抗抑郁药(例如,三环抗抑郁药,四环抗抑郁药,选择性5-羟色胺再摄取抑制剂, 选择性去甲肾上腺素再摄取抑制剂,多巴胺再摄取抑制剂,5-羟色胺去甲肾上腺素再摄取抑制剂,单胺氧化酶抑制剂,5-HT2拮抗剂等)等。
-
公开(公告)号:US20090105277A1
公开(公告)日:2009-04-23
申请号:US11916783
申请日:2006-06-07
申请人: Takako Kadowaki , Minoru Kobayashi , Shizuo Shiozaki , Naoki Seno
发明人: Takako Kadowaki , Minoru Kobayashi , Shizuo Shiozaki , Naoki Seno
IPC分类号: A61K31/496
CPC分类号: C07D487/04 , A61K31/519 , C07D487/14
摘要: For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine A2A receptor antagonistic action, which is represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, R2 represents a hydrogen atom, or the like, R3 represents —WR4, or the like, and Q1 represents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.
摘要翻译: 例如,作为活性成分,含有下述式(I)表示的腺苷A2A受体拮抗作用的三唑并嘧啶衍生物作为活性成分的预防和/或治疗运动障碍的药剂(其中,R1表示取代或未取代的芳基 或取代或未取代的杂环基,R2表示氢原子等,R3表示-WR4等,Q1表示氢原子或3,4-二甲氧基苄基)或其药学上可接受的盐, 喜欢被提供。
-
公开(公告)号:US20060281770A1
公开(公告)日:2006-12-14
申请号:US10553250
申请日:2004-06-10
申请人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
发明人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
IPC分类号: A61K31/522
CPC分类号: A61K45/06 , A61K31/00 , A61K31/519 , A61K31/522 , A61K2300/00
摘要: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要翻译: 通过施用有效量的至少一种腺苷A 2A sub>受体拮抗剂,任选地与除了腺苷A 2A受体拮抗剂之外的抗焦虑药组合。
-
-
-
-
-